1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Coral Laboratories Limited

Coral Laboratories Limited

CORALAB.BO
Coral Laboratories LimitedIN flagBombay Stock Exchange
614.50
INR
+8.95
- -
2.20BMarket Cap
Coral Laboratories Limited
CORALAB.BO
(Bombay Stock Exchange)

Recent

price

614.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
91.53
111.86
116.18
142.2
166.32
205.68
255.63
251.57
247.15
191.04
266.49
204.96
218.03
229.78
321.89
- -
240.46
Revenue per Share
11.65
15.81
16.87
22.02
26.79
34.7
45.61
34.84
28.6
19.96
37.94
25.32
18.04
44.19
67.61
- -
45.86
Basic EPS, GAAP
8.62
7.1
-0.88
2.32
-3.85
11.64
24.53
24.45
-10.35
-14.67
-1.2
1.5
30.01
-18.07
-11.66
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
3.61
6.02
2.41
2.41
- -
- -
- -
- -
2
- -
- -
Dividend per Share
10
97.52
111.8
129.8
153.58
184.67
224.71
313.86
306.68
312
335.2
360.52
378.56
422.71
488.35
- -
10
Book Value per Share
92.69
106.62
121.78
141.49
165.29
196.33
305.3
325.43
318.28
323.65
382.4
436.75
433.24
496.6
562.97
- -
585.21
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
- -
4
Basic Weighted Avg Shares
327
400
415
508
594
735
913
899
883
683
952
732
779
821
1,150
859
859
Sales/Revenue/Turnover
16.35
15.6
15.14
17.28
16.46
20.07
23.84
15.34
11.92
5.01
14.56
8.5
2.09
17.37
21.07
15.22
15.23
Operating Margin (%)
13
13
13
12
26
17
16
16
19
20
20
20
22
20
20
21
21
Depreciation Expense
42
56
60
79
96
124
163
124
102
71
136
90
64
158
242
164
164
Net Income, GAAP
20.7
20.24
20.37
20.69
21.62
28.76
33.66
31.05
34.11
21.79
23.04
23.7
21.65
23.84
25.61
29.13
29.13
Effective Tax Rate (%)
12.73
14.13
14.52
15.49
16.11
16.87
17.84
13.85
11.57
10.45
14.24
12.35
8.27
19.23
21
19.07
19.07
Profit Margin (%)
93
147
206
287
381
466
550
521
656
707
1,011
1,053
1,117
1,290
1,516
1,497
1,497
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
331
381
435
506
591
702
1,092
1,163
1,138
1,157
1,366
1,561
1,548
1,775
2,012
2,091
2,091
Total Equity
12.9
13.96
12.18
14.68
13.78
16.04
15.88
8.29
5.95
2.24
7.87
3.01
0.78
6.28
8.82
4.21
4.21
Return on Invested Capital (%)
83.25
29.55
16.01
18.08
18.65
20.32
21.93
12.7
9.1
6.28
11.17
7.02
4.97
11.03
14.73
17.75
219.62
Return on Capital (%)
116.51
29.41
16.12
18.23
18.91
20.52
22.28
12.94
9.22
6.45
11.72
7.28
4.88
11.03
14.84
18.4
458.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
9
- -
43
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
- -
4
Market Capitalization
1,748
1,567
1,324

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,644
- -
1,770
Cash, Cash Equivalents & STI
1,023
- -
1,019
Accounts Receivable, Net
264
- -
294
Inventories
121
- -
205
Total Current Liabilities
164
- -
273
Payables & Accruals
- -
- -
- -
ST Debt
9
- -
43
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.51%
9.07%
3.93%
Free Cash Flow
148.97%
314.36%
89.96%
Net Income, GAAP
15.36%
20.75%
-32.18%
Sales/Revenue/Turnover
4.12%
0.69%
-25.31%
Total Cash Common Dividend
- -
- -
-25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
135
231
181
273
821
2025
317
322
230
281
1,150
2026
188
190
216
265
859

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.16
16.81
6.04
- -
44.19
2025
24.64
17.86
17.2
7.91
67.61
2026
7.18
16.29
7.77
14.62
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -
Similar Companies
Vasundhara Rasayans Limited (VRL.BO)
Bloomios, Inc. (BLMS)
New Ray Medicine International Holding Ltd. (6108.HK)
Gujarat Themis Biosyn Limited (GUJTHEM.BO)
Kiaro Holdings Corp. (KIARF)
Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF)
Business
Coral Laboratories Limited is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), herbal products, and nutraceuticals. Its core products include prescription medicines, generic drugs, over-the-counter (OTC) healthcare products, and herbal supplements. The company operates primarily in India, serving domestic markets as well as select international markets. Founded in 1984 and headquartered in Mumbai, India, Coral Laboratories delivers comprehensive healthcare solutions encompassing cardiovascular, anti-infective, gastrointestinal, and respiratory therapeutic segments. The company manufactures branded and generic formulations across various dosage forms such as tablets, capsules, injectables, and syrups. Additionally, it offers contract manufacturing services and exports its products to multiple countries. Recent company developments within the last 1-2 years include strategic partnerships aimed at expanding product reach and capital infusion for growth initiatives. Coral Laboratories has undertaken efforts to strengthen its portfolio by launching new products in specialty therapeutic areas and enhancing production capabilities with modernized manufacturing facilities. These moves reflect a strategic focus on expanding domestic market share and exploring international business opportunities. Coral Laboratories operates within the pharmaceutical industry, targeting healthcare providers, pharmacies, hospitals, and wellness retailers. The company maintains a network of subsidiaries and collaborations to support research, development, and marketing efforts. As a listed entity on the Bombay Stock Exchange (ticker: CORALAB.BO), Coral Laboratories emphasizes adherence to regulatory standards and quality compliance in all its operations.